SMS Lifesciences India Ltd. (HALEOSLABS) Share Price Falls 9.02% Amid Market Volatility

SMS Lifesciences India Ltd. Share Price fell 9.02% to Rs 1,440, with a market cap of Rs 478.54 crore.

SMS Lifesciences India Ltd. Share Price experienced a significant decline today, falling 9.02% to close at Rs 1,440. This drop comes in the context of a micro-cap market capitalisation of Rs 478.54 crore. The stock opened at Rs 1,510.05 and reached a high of the same before tumbling to a low of Rs 1,440. The day's turnover was Rs 0.01 crore, with a total volume of 1,180 shares traded across BSE and NSE. Investors are closely monitoring the situation as the stock's performance today has raised questions about its short-term trajectory.

SMS Lifesciences India Ltd. (HALEOSLABS) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,440
Previous Close	Rs 1,582.85
Today's Change	Rs -142.85 (-9.02%)
Day Open	Rs 1,510.05
Day High	Rs 1,510.05
Day Low	Rs 1,440
Current Volume (BSE)	53
BSE Traded Volume	53
NSE Traded Volume	1,127
Combined NSE + BSE Volume	1,180
Turnover	Rs 0.01 crore
Market Capitalisation	Rs 478.54 crore
Market Cap Category	Micro Cap

SMS Lifesciences India Ltd. (HALEOSLABS) traded at Rs 1,440. versus the previous close of Rs 1,582.85, a fall of 9.02%. The stock opened at Rs 1,510.05, reached Rs 1,510.05, touched Rs 1,440. Reported volume was 53.

SMS Lifesciences India Ltd. (HALEOSLABS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 478.54 crore
P/E Ratio	27.64x
P/B Ratio	2.24x
ROE	11.07%
ROCE	12.96%
EPS	Rs 57.26
Dividend Yield	0.09%

SMS Lifesciences India Ltd. was valued at a P/E ratio of 27.64x, a P/B ratio of 2.24x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 11.07% and ROCE of 12.96%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 57.26, dividend yield of 0.09%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

From a fundamental perspective, SMS Lifesciences India Ltd. has a market capitalisation of Rs 478.54 crore. The company's price-to-earnings (P/E) ratio is 27.64, which is slightly above the industry median of 25.82 but below the average of 80.86, indicating a relatively fair valuation. The price-to-book (P/B) ratio stands at 2.24, compared to the industry median of 1.85, suggesting a higher valuation relative to its book value. The return on equity (ROE) is 11.07%, slightly above the industry median of 10.59%, while the return on capital employed (ROCE) is 12.96%, just below the industry median of 12.98%. The company's earnings per share (EPS) is Rs 57.26, and it offers a dividend yield of 0.09%, reflecting a modest payout to shareholders. These fundamentals provide a mixed picture, with some metrics indicating strength while others suggest caution. Investors should weigh these factors carefully when considering the stock's potential.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	27.64x
Benchmark Median P/E	25.82x
Benchmark Average P/E	80.86x
Benchmark P/E Range	3.39x to 3,385.56x
Company P/B Ratio	2.24x
Benchmark Median P/B	1.85x
Company ROE	11.07%
Benchmark Median ROE	10.59%
Company ROCE	12.96%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 478.54 crore
Benchmark Median Market Cap	Rs 146.67 crore

SMS Lifesciences India Ltd. (HALEOSLABS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

SMS Lifesciences India Ltd. (HALEOSLABS) has a P/E ratio of 27.64x, which is above the benchmark median of 25.82x, a difference of +7.05%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

SMS Lifesciences India Ltd. (HALEOSLABS) has a ROE of 11.07%, which is above the benchmark median of 10.59%, a difference of +4.53%. SMS Lifesciences India Ltd. (HALEOSLABS) has a ROCE of 12.96%, which is below the benchmark median of 12.98%, a difference of -0.15%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

SMS Lifesciences India Ltd. operates within the Healthcare sector, specifically in the Pharmaceuticals & Drugs industry. The sector snapshot reveals that the company's P/E ratio of 27.64 is above the industry median of 25.82 but below the average of 80.86, indicating a relatively balanced valuation. The P/B ratio of 2.24 is higher than the industry median of 1.85, suggesting a premium valuation. The company's ROE of 11.07% is slightly above the industry median of 10.59%, while its ROCE of 12.96% is just below the industry median of 12.98%. The market capitalisation of Rs 478.54 crore places it below the industry median of Rs 146.67 crore, highlighting its position as a smaller player in the sector. With 137 companies in the benchmark, SMS Lifesciences India Ltd. faces competition from larger and more established peers. Understanding these sector dynamics is crucial for investors assessing the company's market position and growth potential.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,945.17	30.21	0.44	-2.89	-0.26
Hikal Ltd.	HIKAL	2,835.92	0	2.35	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,652.68	39.86	8.11	28.21	26.35
Beta Drugs Ltd.	BETA	2,608.51	63.2	10	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,589.99	0	3.07	0	5.36

SMS Lifesciences India Ltd. (HALEOSLABS) has a P/E ratio of 27.64x compared with the displayed peer median of 30.21x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.07% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 12.96% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. SMS Lifesciences India Ltd. (HALEOSLABS) has a market capitalisation of Rs 478.54 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

In comparison to its peers, SMS Lifesciences India Ltd. presents a mixed profile. The company's P/E ratio of 27.64 is lower than that of Kwality Pharmaceuticals Ltd. (39.86) and Beta Drugs Ltd. (63.2), but higher than Venus Remedies Ltd. (17.74). Its P/B ratio of 2.24 is comparable to Hikal Ltd. (2.35) and Solara Active Pharma Sciences Ltd. (1.97). The ROE of 11.07% is below Kwality Pharmaceuticals Ltd. (28.21%) but above Venus Remedies Ltd. (9.85%). The ROCE of 12.96% is lower than Beta Drugs Ltd. (22.17%) but higher than Panacea Biotec Ltd. (5.36%). With a market capitalisation of Rs 478.54 crore, SMS Lifesciences India Ltd. is smaller compared to its peers, such as Dishman Carbogen Amcis Ltd. (Rs 2,945.17 crore) and Hikal Ltd. (Rs 2,835.92 crore). These comparisons highlight the company's relative strengths and weaknesses within the industry.

Why Investors Are Watching SMS Lifesciences India Ltd.

Investors are closely monitoring SMS Lifesciences India Ltd. due to its recent price decline and its position within the competitive Pharmaceuticals & Drugs industry. The company's technical and fundamental indicators provide a mixed outlook, prompting further analysis.

• Price Action: 9.02% decline to Rs 1,440.
• Technical Position: RSI at 48.59, below key moving averages.
• Fundamental Context: P/E of 27.64, ROE of 11.07%.
• Ownership: No significant changes reported.
• Sector Positioning: Operates in a competitive industry with 137 peers.

Investors should continue to monitor the company's performance, particularly in light of its valuation metrics and sector dynamics, to make informed decisions.

About SMS Lifesciences India Ltd.

SMS Lifesciences India Ltd. is a prominent player in the Pharmaceuticals & Drugs industry, operating within the broader Healthcare sector. The company is engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio includes a wide range of therapeutic categories, catering to both domestic and international markets. With a focus on quality and innovation, SMS Lifesciences India Ltd. aims to maintain its competitive edge in the industry. The company's operations are supported by state-of-the-art manufacturing facilities and a dedicated research and development team. As a micro-cap entity, it faces challenges from larger competitors but continues to strive for growth and market expansion.

Track SMS Lifesciences India Ltd. Share Price on Univest

Use SMS Lifesciences India Ltd. (HALEOSLABS) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors can track SMS Lifesciences India Ltd. Share Price on Univest for real-time updates and insights. Univest provides comprehensive data on technical indicators, fundamental ratios, shareholding patterns, and 52-week levels. Stay informed with the latest market insights and analysis to make well-informed investment decisions. Univest offers a platform for tracking the performance of SMS Lifesciences India Ltd. and other stocks in the Healthcare sector.

Frequently Asked Questions

What caused the decline in SMS Lifesciences India Ltd. Share Price?

Ans. The decline in SMS Lifesciences India Ltd. Share Price by 9.02% today does not have a specific company-related catalyst. Market volatility and sector dynamics may have influenced the price movement.

What is the current price of SMS Lifesciences India Ltd. shares?

Ans. The current price of SMS Lifesciences India Ltd. shares is Rs 1,440, following a 9.02% decline from the previous close of Rs 1,582.85. The stock moved -9.02% during the session.

How does SMS Lifesciences India Ltd.'s P/E ratio compare to the industry?

Ans. SMS Lifesciences India Ltd.'s P/E ratio of 27.64 is above the industry median of 25.82 but below the industry average of 80.86, indicating a relatively balanced valuation. The company trades at a P/E ratio of 27.64x.

What is the market capitalisation of SMS Lifesciences India Ltd.?

Ans. SMS Lifesciences India Ltd. has a market capitalisation of Rs 478.54 crore, categorising it as a micro-cap company within the Pharmaceuticals & Drugs industry. The company operates in the Healthcare sector.

How does SMS Lifesciences India Ltd.'s ROE compare to its peers?

Ans. SMS Lifesciences India Ltd.'s ROE of 11.07% is below Kwality Pharmaceuticals Ltd. (28.21%) but above Venus Remedies Ltd. (9.85%), indicating a moderate return on equity. ROE stands at 11.07%. ROCE stands at 12.96%.

How does SMS Lifesciences India Ltd.'s P/B ratio compare to the industry?

Ans. SMS Lifesciences India Ltd.'s P/B ratio of 2.24 is higher than the industry median of 1.85, suggesting a premium valuation relative to its book value. The company trades at a P/E ratio of 27.64x.

What is the sector context for SMS Lifesciences India Ltd.?

Ans. SMS Lifesciences India Ltd. operates in the Healthcare sector, specifically in the Pharmaceuticals & Drugs industry, competing with 137 peers in the benchmark. The stock belongs to the Healthcare sector.